Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» review vouchers
review vouchers
Pediatric Priority Review Vouchers Saved in the Eleventh Hour
Pediatric Priority Review Vouchers Saved in the Eleventh Hour
FDA Law Blog
pediatric
review vouchers
FDA
Flag link:
Drug Firms Buy Pricey Vouchers to Speed Products to Market
Drug Firms Buy Pricey Vouchers to Speed Products to Market
WSJ Online
review vouchers
United Therapeutics
FDA
AbbVie
Flag link:
The FDA is lukewarm on those hyper-valuable vouchers for fast drug reviews
The FDA is lukewarm on those hyper-valuable vouchers for fast drug reviews
Fierce Biotech
FDA
priority review
review vouchers
Flag link:
AstraZeneca nabs priority review voucher as Wellstat bags FDA OK
AstraZeneca nabs priority review voucher as Wellstat bags FDA OK
Fierce Biotech
AstraZeneca
FDA
Wellstat
priority review
review vouchers
Xuriden
Flag link:
Sarepta, Biomarin vie for DMD approval, priority review voucher
Sarepta, Biomarin vie for DMD approval, priority review voucher
BioPharma Dive
Sarepta
Biomarin
Duchenne Muscular Dystrophy
FDA
priority review
review vouchers
Flag link:
Why Four Months Is Worth $350m To AbbVie And Filgotinib
Why Four Months Is Worth $350m To AbbVie And Filgotinib
Seeking Alpha
AbbVie
filgotinib
FDA
review vouchers
priority review
Flag link:
Did AbbVie Just Make an Incredibly Brilliant Decision?
Did AbbVie Just Make an Incredibly Brilliant Decision?
Motley Fool
AbbVie
priority review
review vouchers
United Therapeutics
Flag link:
AbbVie buys special review voucher for $350 mln
AbbVie buys special review voucher for $350 mln
Yahoo/Reuters
AbbVie
priority review
review vouchers
United Therapeutics
Flag link:
Retrophin Turns Asklepion Voucher Into $245M Sanofi Payday
Retrophin Turns Asklepion Voucher Into $245M Sanofi Payday
Xconomy
Retrophin
review vouchers
Sanofi
Asklepion Pharmaceuticals
FDA
Flag link:
Novartis is FDA's first priority review voucher recipient for gaining approval of a tropical disease therapy
Novartis is FDA's first priority review voucher recipient for gaining approval of a tropical disease therapy
InVivo
FDA
Novartis
malaria
review vouchers
Coartem
Flag link: